Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 in Parkinson's Disease
NCT03671785Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRIM-DJ2727 in Parkinson's disease (PD) (2 arms), sponsored by UTHealth Houston. Primary endpoints: Microbiome Diversity in Fecal Samples as Indicated by the Shannon Diversity Index at month 9, Microbiome Richness in Fecal Samples as Indicated by the Number of Taxonomies per Participant at month 9 and 1 more. Started May 2019; status: completed.
02
Drugs
PRIM-DJ2727
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03671785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671785.